Recent Updates
Recently added Catalysts
INKT Positive Sentiment Score: 75/100

MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting

Wednesday, March 15, 2023 1 min read
Key Takeaway: MiNK Therapeutics, Inc. has announced that it will present updated clinical data on its allo-iNKT cell therapy, agenT-797, during the AACR Annual Meeting scheduled for April 14-19, 2023. The presentation will include insights into the therapy's application in treating advanced solid tumors, both alone and in combination with approved anti-PD-1 treatments. The update signifies the company's ongoing efforts in pioneering iNKT cell therapies for cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of updated clinical data promises new insights.
  • Focus on innovative allo-iNKT cell therapy shows potential.
  • Combination with approved anti-PD-1 therapy may enhance efficacy.

Full Press Release Details

– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to present updated clinical data and development plans in solid tumors at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19th, 2023.
Presentation Details
Title: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors
Abstract Number: CT275
Session Title: Phase I Clinical Trials 2
Session Date and Time: Tuesday April 18, 2023, 1:30 PM - 5:00 PM ET
Presenting Author: Dr. Benedito Carneiro
About MiNK Therapeutics
communications@minktherapeutics.com
investor@minktherapeutics.com

Frequently Asked Questions

What is agenT-797?

agenT-797 is an allogeneic iNKT cell therapy developed by MiNK Therapeutics.

When will the AACR Annual Meeting take place?

The AACR Annual Meeting is scheduled for April 14-19, 2023.

Who is presenting the clinical update?

Dr. Benedito Carneiro will present the clinical update.

What is the focus of the clinical update?

The update focuses on iNKT cells used alone or with approved anti-PD-1 therapies.

Where can more information about MiNK be found?

More information can be obtained via communications@minktherapeutics.com.

Tags: INKT Viatris Investor Conferences Healthcare MiNK Therapeutics allo-iNKT therapy AACR Annual Meeting agenT-797 solid tumors
Last updated: Mar 15, 2023